Last updated: August 13, 2026
PENNSAID is a prescription topical diclofenac sodium solution for osteoarthritis pain. Its commercial value has shifted from product innovation to lifecycle management. The product benefits from topical delivery and lower systemic exposure than oral NSAIDs, but faces pressure from generic diclofenac products, over-the-counter Voltaren Arthritis Pain gel, oral NSAIDs, and payer substitution.
PENNSAID’s current financial contribution is not separately disclosed by Amgen, which acquired Horizon Therapeutics in 2023. Public filings report Horizon and Amgen portfolio revenue at aggregate levels rather than identifying PENNSAID sales. The product remains commercially relevant but is unlikely to be a material driver of Amgen’s consolidated revenue.
What is PENNSAID and how does it compete in osteoarthritis treatment?
PENNSAID contains diclofenac sodium, a nonsteroidal anti-inflammatory drug, or NSAID. It is applied topically to the knees for osteoarthritis pain.
The product has been marketed in two principal strengths:
| Product |
Active ingredient |
FDA application |
Primary use |
Commercial status |
| PENNSAID 1.5% |
Diclofenac sodium 1.5% |
NDA 022122 |
Knee osteoarthritis pain |
Legacy formulation |
| PENNSAID 2% |
Diclofenac sodium 2% |
NDA 204512 |
Knee osteoarthritis pain |
Current branded formulation |
PENNSAID 2% uses a metered-dose pump and is applied twice daily. PENNSAID 1.5% historically required more frequent application and used a different vehicle. The 2% formulation was designed to improve dosing convenience and product differentiation.
The competitive set includes:
- Voltaren Arthritis Pain gel, an OTC diclofenac sodium 1% gel.
- Generic diclofenac sodium topical solution.
- Generic diclofenac sodium topical gel.
- Oral diclofenac, naproxen, ibuprofen, and other systemic NSAIDs.
- Topical capsaicin and other local analgesics.
- Intra-articular corticosteroid injections and hyaluronic acid products.
- Prescription topical NSAID products in selected international markets.
PENNSAID’s commercial positioning depends on prescription access, metered delivery, knee-specific labeling, and physician familiarity. Its disadvantages include higher out-of-pocket exposure, prior authorization requirements, and therapeutic substitution with less expensive diclofenac gels.
How has PENNSAID’s ownership and commercial history developed?
PENNSAID was developed and commercialized by Nuvo Research. Horizon Pharma acquired rights and assets associated with PENNSAID during its expansion into specialty pharmaceuticals. Horizon later became part of Amgen through Amgen’s acquisition of Horizon Therapeutics, completed in October 2023.
| Period |
Corporate or regulatory event |
| 2009 |
FDA approval of PENNSAID 1.5% under NDA 022122 |
| 2014 |
FDA approval of PENNSAID 2% under NDA 204512 |
| 2014 onward |
Horizon became the principal U.S. commercial owner |
| 2020 onward |
Generic competition increased across topical diclofenac products |
| October 2023 |
Amgen completed acquisition of Horizon Therapeutics |
| 2024 onward |
PENNSAID remained within Amgen’s inherited Horizon portfolio, without separate public revenue reporting |
Horizon’s growth strategy relied on branded specialty products with pricing power and relatively focused commercial infrastructure. PENNSAID fit that model during the period when branded topical diclofenac had limited direct generic competition. Its economic profile changed as generic topical formulations became available and payers expanded substitution controls.
What are PENNSAID’s FDA regulatory and Orange Book statuses?
PENNSAID is an FDA-approved prescription product. The relevant applications are NDA 022122 for PENNSAID 1.5% and NDA 204512 for PENNSAID 2%.
The FDA-approved labeling includes NSAID class warnings relating to cardiovascular thrombotic events, gastrointestinal bleeding, renal effects, hepatic effects, and hypersensitivity. Topical administration generally produces lower systemic exposure than oral diclofenac, but the boxed warning and class-level precautions remain relevant.[1][2]
The Orange Book is the principal source for identifying approved products, reference-listed drugs, therapeutic-equivalence ratings, and patent or exclusivity information. For PENNSAID, commercial risk analysis must distinguish between:
- The branded reference product.
- Approved generic topical solutions.
- Generic topical gels that may be therapeutically substitutable but are not necessarily the same dosage form.
- Legacy patents associated with the 1.5% and 2% products.
- Any remaining pediatric, clinical, or regulatory exclusivity.
No long-duration regulatory exclusivity is the central protection for PENNSAID today. Its commercial defense depends primarily on formulation differentiation, brand recognition, payer contracting, prescription demand, and manufacturing know-how.
What patents protect PENNSAID?
PENNSAID’s protection has historically centered on formulation and delivery technology rather than composition of matter. Diclofenac sodium is an old active ingredient and is not protected by a modern foundational molecule patent.
Relevant patent categories include:
| Patent category |
Protection target |
Business impact |
| Vehicle patents |
Solubilization of diclofenac in a topical liquid |
Can delay identical solution competition |
| Delivery patents |
Metered-dose administration and skin delivery |
Supports dosing and usability differentiation |
| Formulation patents |
Concentration, excipients, penetration enhancers, and stability |
May create product-specific barriers |
| Method-of-use patents |
Treatment of osteoarthritis pain, particularly knee pain |
Usually weaker than composition patents |
| Manufacturing patents |
Mixing, filling, packaging, and quality controls |
Can raise entry costs but rarely blocks all alternatives |
The most important practical distinction is between a patent covering PENNSAID’s exact formulation and a patent covering a broader topical diclofenac concept. A generic manufacturer can sometimes avoid a formulation patent by changing excipients, concentration, delivery system, or manufacturing process.
Because PENNSAID’s active ingredient is off-patent, formulation patents have lower exclusionary strength than composition-of-matter patents. Their value depends on claim breadth, remaining term, prosecution history, infringement evidence, and whether the FDA-approved generic must use the claimed formulation.
When does PENNSAID lose exclusivity and face generic entry?
PENNSAID’s principal exclusivity risk is already active rather than concentrated in a single future cliff.
The 1.5% product received FDA approval in 2009, and the 2% product received approval in 2014. Any ordinary five-year new chemical entity exclusivity associated with the relevant NDA has expired. Formulation patents may extend protection beyond regulatory exclusivity, but their remaining value depends on specific listing and litigation outcomes.
Generic entry scenarios include:
Same-strength topical solution entry
An ANDA applicant can seek approval for a generic diclofenac sodium topical solution that matches the reference product’s strength, dosage form, route, and labeling. This is the highest direct substitution risk.
Alternative topical diclofenac entry
Generic diclofenac gel products compete for the same patients even when they are not exact pharmaceutical equivalents to PENNSAID solution. Pharmacists and payers may encourage substitution based on cost and therapeutic category.
Payer-driven substitution
Commercial insurers and pharmacy benefit managers can place generic diclofenac products on preferred tiers, impose prior authorization on PENNSAID, or require failure of lower-cost topical NSAIDs before coverage.
OTC substitution
The launch of Voltaren Arthritis Pain as an over-the-counter product expanded consumer access to diclofenac 1% gel. OTC availability reduces the need for a prescription topical NSAID in some patients, although the dosage form and labeled use differ from PENNSAID.
Which companies are challenging PENNSAID commercially?
PENNSAID faces competition from generic manufacturers rather than a single dominant branded challenger. The competitive field can include companies marketing:
- Diclofenac sodium topical solution.
- Diclofenac sodium topical gel.
- Other prescription topical NSAIDs.
- OTC diclofenac products.
The leading commercial threat is low-cost generic diclofenac. Generic manufacturers can compete without reproducing every commercial attribute of PENNSAID if they obtain FDA approval for a therapeutically substitutable product or target the same payer and prescriber channels.
Voltaren, owned by Haleon in the consumer-health market, is a separate commercial competitor. Its OTC status gives it distribution through mass retail, pharmacies, and e-commerce. PENNSAID retains an advantage in prescription positioning and metered solution delivery, but that advantage is limited when insurers focus on net cost.
How strong is the PENNSAID patent estate?
PENNSAID has a moderate-to-weak current patent position compared with innovative drugs protected by composition-of-matter patents.
Strengths
- Topical formulation claims can delay an exact-copy solution.
- Metered-dose delivery may support product differentiation.
- The product has established prescriber recognition.
- Regulatory labeling and manufacturing experience create execution advantages.
- Some patients may prefer a liquid solution over a gel.
Weaknesses
- Diclofenac sodium is an old, widely available active ingredient.
- The principal protection is formulation-based.
- Generic gels and solutions can attack the same clinical demand through different formulations.
- Payer substitution can reduce branded volume before full generic penetration.
- Amgen does not identify PENNSAID as a major standalone growth asset in its public reporting.
The estate is therefore more useful for managing price and channel erosion than for preserving a long-term monopoly.
What is PENNSAID’s financial trajectory?
PENNSAID revenue is not separately reported in current Amgen public filings. Horizon disclosed product and portfolio results in varying levels of detail during its ownership period, but PENNSAID was not consistently presented as a standalone material revenue line in the company’s later reporting.
The likely trajectory has four phases:
| Phase |
Revenue pattern |
Main driver |
| Initial launch |
Low base with prescription adoption |
FDA approval and physician education |
| Branded expansion |
Growth in prescriptions and price realization |
Horizon commercial execution |
| Lifecycle transition |
Slower growth and rising payer friction |
Generic topical competition |
| Mature portfolio |
Stable or declining nominal sales |
Price concessions, substitution, and reduced promotion |
The key financial variables are:
- Gross-to-net discounts.
- Commercial-plan coverage.
- Medicare Part D positioning.
- Generic dispensing rates.
- Patient copay assistance.
- Prescription volume.
- Net price per prescription.
- Promotional spending.
- Whether Amgen maintains active specialty-pharmacy support.
For an acquirer or licensing party, the absence of separately disclosed revenue makes independent valuation more difficult. The product should be analyzed through prescription data, claims data, channel inventory, payer coverage, and pharmacy-level generic substitution rather than corporate revenue alone.
What licensing deals affect PENNSAID?
PENNSAID’s ownership history reflects asset and company-level transactions rather than a widely disclosed current standalone licensing transaction.
Nuvo Research was the original developer. Horizon later obtained control of the product and incorporated it into a broader specialty-pharmaceutical portfolio. Amgen acquired Horizon in a transaction valued at approximately $27.8 billion, including assumed debt, bringing PENNSAID under Amgen ownership.[3]
The commercial significance of that transaction is limited for PENNSAID because Amgen’s investment case centered on Horizon’s larger assets, particularly Tepezza, Krystexxa, and Uplizna. PENNSAID is a legacy revenue contributor within the acquired portfolio, not a principal transaction driver.
What generic launch risks exist for PENNSAID?
The highest-risk scenario is a same-strength generic solution with an FDA therapeutic-equivalence rating that allows pharmacy substitution. The timing and impact would depend on the number of approved manufacturers and whether any applicant receives first-filer or other market advantages.
| Risk factor |
Effect on PENNSAID |
| One generic entrant |
Moderate price and volume pressure |
| Multiple generic entrants |
Rapid net-price erosion |
| Preferred payer placement |
Accelerated substitution |
| Limited generic capacity |
Slower erosion |
| Strong patient brand loyalty |
Partial retention |
| OTC Voltaren availability |
Expanded nonprescription substitution |
| Formulation-specific patent enforcement |
Potential delay to identical entry |
Generic erosion would likely affect volume first in managed-care channels. Cash-pay and physician-directed patients may retain branded demand longer, particularly where the prescription solution is viewed as more convenient than OTC gel.
How does PENNSAID compare with Voltaren and generic diclofenac?
| Attribute |
PENNSAID |
Voltaren Arthritis Pain |
Generic diclofenac |
| Status |
Prescription |
OTC |
Prescription or OTC, depending on product |
| Active ingredient |
Diclofenac sodium |
Diclofenac sodium |
Diclofenac sodium |
| Main dosage form |
Topical solution |
Topical gel |
Gel or topical solution |
| Strength commonly associated with product |
1.5% or 2% |
1% |
Varies |
| Target use |
Knee osteoarthritis pain |
Arthritis pain |
Depends on label |
| Payer economics |
Higher branded cost |
Consumer-paid or covered selectively |
Lowest-cost option in many plans |
| Main advantage |
Metered prescription solution |
Retail availability |
Price |
| Main weakness |
Brand and coverage cost |
Different dosage form and OTC payment |
Limited brand support |
PENNSAID’s defensible niche is a prescription topical solution with established labeling and delivery characteristics. Its market share is vulnerable when payers treat topical diclofenac products as interchangeable therapeutic alternatives.
What litigation and settlement issues affect PENNSAID?
PENNSAID litigation risk is principally associated with Paragraph IV challenges to listed formulation patents, patent-infringement actions under the Hatch-Waxman Act, and potential settlements governing generic launch dates.
A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. If the reference-product owner files suit within the statutory period, FDA approval may be subject to a 30-month stay, subject to statutory exceptions and court rulings.
The practical questions for investors are:
- Which PENNSAID patents were listed for each NDA?
- Which patents remained unexpired when the ANDA was filed?
- Did an ANDA applicant make a Paragraph IV certification?
- Was litigation filed within the applicable deadline?
- Did the parties agree to a licensed entry date?
- Did the settlement include restrictions on authorized generic supply or formulation changes?
A definitive current litigation and settlement inventory requires live review of FDA Orange Book records, federal court dockets, and company disclosures. The available public financial materials do not identify PENNSAID litigation as a material current corporate event.
What is the outlook for PENNSAID revenue?
PENNSAID is best viewed as a mature specialty product with declining strategic importance but continuing cash-flow potential. Revenue stability depends on retaining prescriptions in channels where the solution formulation has a practical advantage and where generic substitution is incomplete.
The base-case commercial outlook is:
- Limited unit growth.
- Continued pressure from generic topical diclofenac.
- Higher payer scrutiny.
- Reduced ability to raise price.
- Gradual decline in branded net sales.
- Continued contribution from patients who prefer prescription topical solution.
- Low probability of major portfolio investment absent a new indication, formulation, or channel strategy.
The product’s value is greater as a managed legacy asset than as a platform for substantial future growth.
Key Takeaways
- PENNSAID is a prescription diclofenac sodium topical solution for knee osteoarthritis pain.
- FDA approvals include NDA 022122 for PENNSAID 1.5% and NDA 204512 for PENNSAID 2%.
- Horizon Therapeutics commercialized the product before Amgen acquired Horizon in 2023.
- Amgen does not separately disclose PENNSAID revenue.
- Composition-of-matter protection is unavailable because diclofenac sodium is an established active ingredient.
- Formulation, delivery, and manufacturing patents provide narrower protection than molecule patents.
- Generic topical diclofenac and OTC Voltaren are the main commercial threats.
- The product has mature-asset economics, with likely long-term pressure on volume and net price.
- The principal investment issue is residual cash flow, not high-growth potential.
FAQs
Does PENNSAID contain the same drug as Voltaren?
Yes. Both contain diclofenac, although PENNSAID is a prescription topical solution and Voltaren Arthritis Pain is an OTC diclofenac sodium gel with different strength, formulation, labeling, and use conditions.
Is PENNSAID still protected by a composition-of-matter patent?
No. Diclofenac sodium is an old active ingredient. Any remaining protection is more likely to involve formulation, delivery, manufacturing, or use claims.
Can a pharmacy automatically substitute generic diclofenac for PENNSAID?
Substitution depends on the generic product’s FDA therapeutic-equivalence rating, state pharmacy law, prescription instructions, payer policy, and whether the generic is the same dosage form and strength.
Why does Amgen not report PENNSAID sales separately?
Amgen aggregates many products within broader revenue categories. PENNSAID is not identified as a material standalone revenue driver in the company’s public reporting.
Is PENNSAID a biologic with biosimilar risk?
No. PENNSAID is a small-molecule diclofenac product. Its competitive risk comes from generic drug approval pathways, not biosimilar competition.
References
-
U.S. Food and Drug Administration. (2023). PENNSAID 2% diclofenac sodium topical solution prescribing information. FDA.
-
U.S. Food and Drug Administration. (2009). PENNSAID 1.5% diclofenac sodium topical solution approval history and labeling. FDA.
-
Amgen Inc. (2023). Amgen completes acquisition of Horizon Therapeutics plc. Amgen investor relations.
-
Amgen Inc. (2024). 2023 annual report. Amgen.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
-
Horizon Therapeutics plc. (2022). Annual report for the year ended December 31, 2022. Horizon Therapeutics.
